S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Journal ArticleDOI
dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function.
TL;DR: A novel MOA for an anticancer agent involving triggering of apoptosis through induction of opposite effects: ER stress and downregulation of the ER stress repair mechanism is investigated and provides the framework for the clinical evaluation of dTCApFs.
Journal ArticleDOI
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
Adi Jacob Berger,Elinor Gigi,Lana Kupershmidt,Zohar Meir,Nancy Gavert,Yaara Zwang,Amir Pri-Or,Shlomit Gilad,Uzi Harush,Izhak Haviv,Salomon M. Stemmer,Galia Blum,Emmanuelle Merquiol,Mariya Mardamshina,Sivan Kaminski Strauss,Gilgi Friedlander,Jair Bar,Iris Kamer,Yitzhak Reizel,Tamar Geiger,Yitzhak Pilpel,Yishai Levin,Amos Tanay,Baruch Barzel,Hadas Reuveni,Ravid Straussman +25 more
TL;DR: This article showed that cancer cells actually possess a highly stable inherited chance to persist (CTP) during therapy, which is non-stochastic, determined pre-treatment and has a unimodal distribution ranging from 0 to almost 100%.
Journal ArticleDOI
Uncommon Reason for High Fluorodeoxyglucose Positron Emission Tomography Uptake
TL;DR: The patient was breast-feeding her three-month-old newborn, which provides an uncommon reason for high FDG uptake that is not widely recognized as a cause for a false-positive PET scan in clinical practice.
Journal ArticleDOI
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
C.C. Zielinski,István Láng,Moshe Inbar,Zsuzsanna Kahán,Richard Greil,Semir Beslija,Salomon M. Stemmer,Z. Zvirbule,Günther G. Steger,Bohuslav Melichar,Tadeusz Pienkowski,D. Sirbu,Lubos Petruzelka,Alexandru Eniu,Bella Nisenbaum,M. Dank,Rodica Anghel,Diethelm Messinger,T. Brodowicz +18 more
Journal ArticleDOI
Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
Noa Eliakim-Raz,Amos Stemmer,Yaara Leibovici-Weisman,Asaf Ness,Muhammad Awwad,N. Ghantous,Noam Erez,Avital Bareket-Samish,Adva Levy-Barda,Haim Ben-Zvi,Neta Moskovits,Erez Bar-Haim,Salomon M. Stemmer +12 more
TL;DR: Anti-spike IgG and neutralising antibody levels remain adequate 3 months after the third BNT162b2 vaccine in healthy adults aged ≥60 years, although the decline in IgG is concerning.